ERBB2 and breast cancer: Conversely, mutations in ATM do not affect age at diagnosis: Patients with germline or somatic ATM mutations remain postmenopausal with median ages of 61 and 54 years, respectively, as expected for patients with ER+/HER2− breast cancer (Fig. 2D).